Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Annis

Interventional Pain Medicine Elkhart, IN Medical Doctor

NPI 1376760827 CMS profile 17558

2310 California Rd, Elkhart, IN 46514

Open in the dashboard

General payments

$4,157

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Annis of Elkhart, IN is reported in the CMS Open Payments database as having received $4,157 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,518 31
2024 General $786 15
2023 General $239 10
2022 General $787 16
2021 General $110 4
2020 General $263 8
2019 General $454 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Annis
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Christopher Annis were reported at $1,518. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Christopher Annis Interventional Pain Medicine median Middle half National median
2019 $454 $684 $216–$2,079 $163
2020 $263 $382 $122–$1,109 $114
2021 $110 $552 $167–$1,554 $132
2022 $787 $605 $187–$1,924 $149
2023 $239 $671 $195–$1,915 $160
2024 $786 $684 $206–$1,837 $164
2025 $1,518 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,337 56 payments
  2. Abbott Laboratories $565 9 payments
  3. Globus Medical, Inc. $479 7 payments
  4. Nevro Corp. $258 9 payments
  5. Inspire Medical Systems, Inc. $164 4 payments
  6. Portola Pharmaceuticals, Inc. $138 1 payment
  7. Flexion Therapeutics, Inc. $106 1 payment
  8. Stryker Corporation $67 1 payment
  9. Boston Scientific Corporation $15 1 payment
  10. Vertos Medical, Inc. $14 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,157 91 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $1,557 35 payments
  2. Senza $479 7 payments
  3. Accurian $244 5 payments
  4. Proclaim Family of SCS IPGs $235 4 payments
  5. SYNCHROMEDII $219 5 payments
  6. Senza Spinal Cord Stimulation System $209 7 payments
  7. PROCLAIM $174 2 payments
  8. ELEVATE SPINAL SYSTEM $173 1 payment
  9. INSPIRE $164 4 payments
  10. ANDEXXA $138 1 payment
  11. Other $566 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

3,002

Median for Pain Management: 951

Drug cost

$59,835

Median for Pain Management: $26,034

Branded share of claims

28.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 522 $12,449
Nucynta Tapentadol Hcl Brand 11 $7,503
Gabapentin Generic 490 $5,983
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 264 $5,846
Pregabalin Generic 177 $3,847
Xtampza Er Oxycodone Myristate Brand 15 $3,559
Tramadol Hcl Generic 353 $3,180
Celecoxib Generic 73 $2,278
Duloxetine Hcl Generic 147 $2,096
Lidocaine Generic 20 $1,914

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$143,109

Of which drugs: $11,966

Medicare patients

441

Average age 76

Services billed

2,350

294 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Chronic kidney disease 30%
Depression 30%
Diabetes 28%
Osteoporosis 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 30 176 $962

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record